Cancer drug developer RenovoRx's Q3 net loss widens

Reuters11-14

Cancer drug developer RenovoRx's Q3 net loss widens

Overview

RenovoRx Q3 revenue at $266,000, reflecting early-stage commercialization progress
Net loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in Q3 2024
Company expects revenue growth in 2026 to offset cash burn

Outlook

RenovoRx expects revenue growth in 2026 to offset cash burn
RenovoRx plans strategic expansion with increased physician advocacy

Result Drivers

COMMERCIAL EXPANSION - RenovoRx expanded from 5 to 14 cancer centers approved to purchase RenovoCath, reflecting growing market adoption
SALES TEAM GROWTH - Co hired new sales leadership, including Philip Stocton as Senior Director of Sales, to support commercialization

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$2.91 mln
Q3 Basic EPS		-$0.08
Q3 Operating Expenses		$3.41 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for RenovoRx Inc is $3.75, about 73.3% above its November 12 closing price of $1.00

Press Release: ID:nGNX8XzfdS

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583120795?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583120795","market":"nz","top_or_hot":-1,"title":"Cancer drug developer RenovoRx's Q3 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer drug developer RenovoRx's Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>RenovoRx Q3 revenue at $266,000, reflecting early-stage commercialization progress</p></li><li><p>Net loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in Q3 2024</p></li><li><p>Company expects revenue growth in 2026 to offset cash burn</p></li></ul><p><span>Outlook</span></p><ul><li><p>RenovoRx expects revenue growth in 2026 to offset cash burn</p></li><li><p>RenovoRx plans strategic expansion with increased physician advocacy</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COMMERCIAL EXPANSION - RenovoRx expanded from 5 to 14 cancer centers approved to purchase RenovoCath, reflecting growing market adoption</p></li><li><p>SALES TEAM GROWTH - Co hired new sales leadership, including Philip Stocton as Senior Director of Sales, to support commercialization</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.91 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.08</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$3.41 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/RNXT\">RenovoRx Inc</a> is $3.75, about 73.3% above its November 12 closing price of $1.00</p></li></ul><p>Press Release: <span>ID:nGNX8XzfdS</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cancer drug developer RenovoRx's Q3 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCancer drug developer RenovoRx's Q3 net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer drug developer RenovoRx's Q3 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>RenovoRx Q3 revenue at $266,000, reflecting early-stage commercialization progress</p></li><li><p>Net loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in Q3 2024</p></li><li><p>Company expects revenue growth in 2026 to offset cash burn</p></li></ul><p><span>Outlook</span></p><ul><li><p>RenovoRx expects revenue growth in 2026 to offset cash burn</p></li><li><p>RenovoRx plans strategic expansion with increased physician advocacy</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COMMERCIAL EXPANSION - RenovoRx expanded from 5 to 14 cancer centers approved to purchase RenovoCath, reflecting growing market adoption</p></li><li><p>SALES TEAM GROWTH - Co hired new sales leadership, including Philip Stocton as Senior Director of Sales, to support commercialization</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$2.91 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.08</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$3.41 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/RNXT\">RenovoRx Inc</a> is $3.75, about 73.3% above its November 12 closing price of $1.00</p></li></ul><p>Press Release: <span>ID:nGNX8XzfdS</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP18R:1","article_id":"2583120795","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583120795","pubTimestamp":1763069880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cancer drug developer RenovoRx's Q3 net loss widensOverviewRenovoRx Q3 revenue at $266,000, reflecting early-stage commercialization progressNet loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","RNXT":"RenovoRx Inc","BK4139":"生物科技"},"translate_title":"癌症药物开发商RenovoRx第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNXT":0.9},"content_text":"Cancer drug developer RenovoRx's Q3 net loss widensOverviewRenovoRx Q3 revenue at $266,000, reflecting early-stage commercialization progressNet loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in Q3 2024Company expects revenue growth in 2026 to offset cash burnOutlookRenovoRx expects revenue growth in 2026 to offset cash burnRenovoRx plans strategic expansion with increased physician advocacyResult DriversCOMMERCIAL EXPANSION - RenovoRx expanded from 5 to 14 cancer centers approved to purchase RenovoCath, reflecting growing market adoptionSALES TEAM GROWTH - Co hired new sales leadership, including Philip Stocton as Senior Director of Sales, to support commercializationKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$2.91 mlnQ3 Basic EPS-$0.08Q3 Operating Expenses$3.41 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"Wall Street's median 12-month price target for RenovoRx Inc is $3.75, about 73.3% above its November 12 closing price of $1.00Press Release: ID:nGNX8XzfdSFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583120795","isCrawlerRequest":true}